Detalhe da pesquisa
1.
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.
Cell
; 184(8): 2167-2182.e22, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33811809
2.
Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases.
Med Res Rev
; 41(1): 223-245, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32926459
3.
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.
Cardiovasc Diabetol
; 20(1): 125, 2021 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34158057
4.
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study.
Cardiovasc Diabetol
; 20(1): 13, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33413345
5.
Pharmacologic epigenetic modulators of alkaline phosphatase in chronic kidney disease.
Curr Opin Nephrol Hypertens
; 29(1): 4-15, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31725015
6.
Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.
Am J Respir Crit Care Med
; 200(7): 910-920, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31042405
7.
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.
JAMA
; 323(16): 1565-1573, 2020 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32219359
8.
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial.
Am Heart J
; 217: 72-83, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31520897
9.
Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease.
Kidney Blood Press Res
; 43(2): 449-457, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29566379
10.
BET Protein Inhibition for Pulmonary Arterial Hypertension: A Pilot Clinical Trial.
Am J Respir Crit Care Med
; 205(11): 1357-1360, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35289736
11.
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.
Mol Pharmacol
; 92(6): 694-706, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28974538
12.
Reply to Piquereau and Perros and to Pullamsetti and de Jesus Perez.
Am J Respir Crit Care Med
; 200(9): 1190-1191, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31419387
13.
Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells.
Biomedicines
; 11(10)2023 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37893058
14.
Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells.
Atherosclerosis
; 364: 10-19, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36455344
15.
Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation.
Int Immunopharmacol
; 117: 109929, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36857935
16.
Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment.
Biomedicines
; 11(6)2023 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37371758
17.
The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation.
Transl Neurosci
; 14(1): 20220332, 2023 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38222824
18.
Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
Am J Prev Cardiol
; 11: 100372, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36039183
19.
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy.
Pharmacol Res Perspect
; 10(3): e00949, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35417091
20.
Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators.
Biomed Pharmacother
; 152: 113230, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35687908